These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 28566335)

  • 1. Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine.
    Lujan E; Partridge E; Giuntini S; Ram S; Granoff DM
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28566335
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Meningococcal Outer Membrane Vesicle Vaccine with Overexpressed Mutant FHbp Elicits Higher Protective Antibody Responses in Infant Rhesus Macaques than a Licensed Serogroup B Vaccine.
    Beernink PT; Vianzon V; Lewis LA; Moe GR; Granoff DM
    mBio; 2019 Jun; 10(3):. PubMed ID: 31213564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.
    Rossi R; Beernink PT; Giuntini S; Granoff DM
    Clin Vaccine Immunol; 2015 Dec; 22(12):1227-34. PubMed ID: 26424832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Meningococcal serogroup B vaccines: Estimating breadth of coverage.
    Donald RG; Hawkins JC; Hao L; Liberator P; Jones TR; Harris SL; Perez JL; Eiden JJ; Jansen KU; Anderson AS
    Hum Vaccin Immunother; 2017 Feb; 13(2):255-265. PubMed ID: 27960595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A meningococcal NOMV-FHbp vaccine for Africa elicits broader serum bactericidal antibody responses against serogroup B and non-B strains than a licensed serogroup B vaccine.
    Pajon R; Lujan E; Granoff DM
    Vaccine; 2016 Jan; 34(5):643-649. PubMed ID: 26709637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci.
    Giuntini S; Lujan E; Gibani MM; Dold C; Rollier CS; Pollard AJ; Granoff DM
    Clin Vaccine Immunol; 2017 Jan; 24(1):. PubMed ID: 27847367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of anti-NHba antibody in bactericidal activity elicited by the meningococcal serogroup B vaccine, MenB-4C.
    Partridge E; Lujan E; Giuntini S; Vu DM; Granoff DM
    Vaccine; 2017 Jul; 35(33):4236-4244. PubMed ID: 28651840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. From research to licensure and beyond: clinical development of MenB-FHbp, a broadly protective meningococcal B vaccine.
    Perez JL; Absalon J; Beeslaar J; Balmer P; Jansen KU; Jones TR; Harris S; York LJ; Jiang Q; Radley D; Anderson AS; Crowther G; Eiden JJ
    Expert Rev Vaccines; 2018 Jun; 17(6):461-477. PubMed ID: 29883226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence and 4-year boosting of the bactericidal response elicited by two- and three-dose schedules of MenB-FHbp: A phase 3 extension study in adolescents.
    Vesikari T; Østergaard L; Beeslaar J; Absalon J; Eiden JJ; Jansen KU; Jones TR; Harris SL; Maansson R; Munson S; O'Neill RE; York LJ; Perez JL
    Vaccine; 2019 Mar; 37(12):1710-1719. PubMed ID: 30770221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bactericidal activity of sera from adolescents vaccinated with bivalent rLP2086 against meningococcal serogroup B outbreak strains from France.
    Taha MK; Hawkins JC; Liberator P; Deghmane AE; Andrew L; Hao L; Jones TR; McNeil LK; O'Neill RE; Perez JL; Jansen KU; Anderson AS
    Vaccine; 2017 Mar; 35(11):1530-1537. PubMed ID: 28196734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.
    Peterson J; Drazan D; Czajka H; Maguire J; Pregaldien JL; Seppa I; Maansson R; O'Neill R; Balmer P; Jodar L; Jansen KU; Anderson AS; Perez JL; Beeslaar J
    Lancet Infect Dis; 2023 Dec; 23(12):1370-1382. PubMed ID: 37579773
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bivalent factor H binding protein meningococcal serogroup B vaccine elicits bactericidal antibodies against representative non-serogroup B meningococci.
    Harris SL; Tan C; Andrew L; Hao L; Liberator PA; Absalon J; Anderson AS; Jones TR
    Vaccine; 2018 Oct; 36(45):6867-6874. PubMed ID: 30269916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-Factor H Antibody Reactivity in Young Adults Vaccinated with a Meningococcal Serogroup B Vaccine Containing Factor H Binding Protein.
    Sharkey K; Beernink PT; Langley JM; Gantt S; Quach C; Dold C; Liu Q; Galvan M; Granoff DM
    mSphere; 2019 Jul; 4(4):. PubMed ID: 31270173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic characterization and estimated 4CMenB vaccine strain coverage of 284
    Efron A; Brozzi A; Biolchi A; Bodini M; Giuliani M; Guidotti S; Lorenzo F; Moscoloni MA; Muzzi A; Nocita F; Pizza M; Rappuoli R; Tomei S; Vidal G; Vizzotti C; Campos J; Sorhouet Pereira C
    Hum Vaccin Immunother; 2024 Dec; 20(1):2378537. PubMed ID: 39037011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimated susceptibility of Canadian meningococcal B isolates to a meningococcal serogroup B vaccine (MenB-FHbp).
    Bettinger JA; Liberator P; Halperin SA; Vaudry W; Sadarangani M; Hao L; Lambert N; Jansen KU; Anderson AS; Tsang R;
    Vaccine; 2020 Feb; 38(8):2026-2033. PubMed ID: 31983586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults.
    Ostergaard L; Vesikari T; Absalon J; Beeslaar J; Ward BJ; Senders S; Eiden JJ; Jansen KU; Anderson AS; York LJ; Jones TR; Harris SL; O'Neill R; Radley D; Maansson R; Prégaldien JL; Ginis J; Staerke NB; Perez JL;
    N Engl J Med; 2017 Dec; 377(24):2349-2362. PubMed ID: 29236639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
    Gandhi A; Balmer P; York LJ
    Postgrad Med; 2016 Aug; 128(6):548-56. PubMed ID: 27467048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Bactericidal Antibody Responses of Students Immunized With a Meningococcal Serogroup B Vaccine in Response to an Outbreak on a University Campus.
    Lujan E; Winter K; Rovaris J; Liu Q; Granoff DM
    Clin Infect Dis; 2017 Oct; 65(7):1112-1119. PubMed ID: 28582542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bivalent Neisseria meningitidis recombinant lipidated factor H binding protein vaccine in young adults: results of a randomised, controlled, dose-escalation phase 1 trial.
    Richmond PC; Nissen MD; Marshall HS; Lambert SB; Roberton D; Gruber WC; Jones TR; Arora A
    Vaccine; 2012 Sep; 30(43):6163-74. PubMed ID: 22871351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease.
    Jiang HQ; Hoiseth SK; Harris SL; McNeil LK; Zhu D; Tan C; Scott AA; Alexander K; Mason K; Miller L; DaSilva I; Mack M; Zhao XJ; Pride MW; Andrew L; Murphy E; Hagen M; French R; Arora A; Jones TR; Jansen KU; Zlotnick GW; Anderson AS
    Vaccine; 2010 Aug; 28(37):6086-93. PubMed ID: 20619376
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.